Important adverse events included infusion-related and hypersensitivity reactions in 25 of 306 immunocompromised participants (8.2%) who received pemivibart and anaphylaxis in 4 of 623 participants (0 ...
For the first time this fall, families will be offered season-long protection for infants and some children against respiratory syncytial virus (RSV). The US Food and Drug Administration (FDA) in July ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback